- Wednesday, November 18, 2026

The role of the primary care physicians (PCPs) will become even more important in the coming year as the new leadership of the U.S. Preventive Services Task Force (USPSTF), recently appointed by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., considers adoption of the first kidney disease screening recommendation in American history.

Kidney disease is one of the quietest threats to American health, lives and livelihoods. Its reputation as the “silent killer” is well established. In its earliest stages, chronic kidney disease (CKD) rarely announces itself. There is often no pain and there are no obvious warning signs. Many people feel entirely well even as their kidney function steadily declines. When symptoms do appear, the window for the most proactive and effective interventions, including new FDA-approved drugs that slow disease progress and help prevent the need for dialysis, has closed considerably. This is why PCPs medical professionals best equipped to detect subtle signs of early disease onset have disproportionate influence in determining your future health, capacity to maintain work and mortality. In many instances, by the time a patient is referred to a nephrologist, or kidney specialist, the opportunity to change the trajectory of kidney disease has been lost. Tragically, over 50% of Americans living on dialysis today were first diagnosed with kidney failure in an emergency room a preventable and avoidable burden to people and society.

Why upstream matters

People were interested in these podcasts

PCPs see patients routinely, know their history and family medical history and are trained to detect risk factors and interpret lab tests that signal kidney function decline. Simple, inexpensive tests, such as a blood test for kidney function and a urine test to detect protein, can identify kidney disease before a crisis. When PCPs order these tests, interpret the results and act on the findings, patients can choose among treatments while they still have kidney function to preserve. New federal policies, including the Kidney Care National Plan, prioritize upstream interventions and aim to improve people’s health, quality of life and survival, while preventing disability. Investment in screening, timely diagnosis and early management in primary care is not simply common-sense medicine; it is sound public policy to make America healthier.

The need is urgent. According to the Centers for Disease Control and Prevention (CDC), more than 1 in 10 U.S. adults (14%, or about 37 million people) are estimated to have CKD, yet nearly 9 in 10 adults with CKD are unaware they have it. Among adults with moderate or advanced CKD, only about 1 in 4 are aware of the disease. The CDC noted that this gap could be addressed by screening people with risk factors such as diabetes or high blood pressure. Clinical guidelines say CKD prevention and screening should take place in primary care. Yet, tragically, a 2025 systematic review found substantial underuse of primary care for CKD screening in America.

The gap is most visible in urine testing. A 2025 meta-analysis found that only about 1 in 5 adults with diabetes or high blood pressure received the recommended urine albumin test (uACR) in routine practice. In a study of 24 U.S. healthcare organizations, blood-based eGFR testing of primary care patients with Type 2 diabetes (T2D) was uniformly high, but uACR testing was suboptimal and varied widely. The reasons are practical, not a lack of concern. A systematic review of PCPs found the most common barrier was lack of time. Another barrier was worry about causing patients anxiety by delivering a CKD diagnosis. Other PCPs cited frustration with confusing national care guidelines that change regularly. PCPs also pointed to inflexible electronic medical records and poor Medicare reimbursement for complex CKD care, particularly when managing care for patients with multiple conditions. The same PCPs offered solutions: electronic prompts and lab result support, concise guidelines and Medicare reimbursement reform. These tools can be created through more intelligent and patient-centered federal policies.

Keeping working-age Americans at work

Early disease diagnosis allows working-age Americans to remain in their jobs and the workforce and avoid disability and dependency typically associated with status quo dialysis. The financial benefits for patients and their families are profound. Detecting and managing kidney disease early helps patients maintain their income, savings and stability while reducing costs to taxpayers and society.

The stakes are significant: 53% of people with CKD are of working age. CKD is not only a disease of older age: CDC estimates that 13% of adults aged 45 to 64 and 6% of adults aged 18 to 44 have CKD. The National Kidney Foundation (NKF) reports that roughly 1 in 10 working-age adults has CKD, again, most without knowing it. For those individuals, keeping a job and work-related health benefits helps ensure timely access to the early, preventive care needed to avoid kidney failure. Employment equates to continued health coverage, regular medical appointments and consistent access to medications. By remaining in the workforce, patients remain active, productive, taxpaying citizens. By contrast, a late diagnosis can set off a tragic and unexpected chain of events, including job loss, financial crisis and family instability. Research proves this point. Studies of patients initiating dialysis have found that unemployment affects up to 75% of people beginning treatment for kidney failure and that about half of those who reach kidney failure are of working age. In 2023, about 131,564 Americans started treatment for kidney failure and about 831,000 were living with it, two-thirds of them on dialysis.

The societal return on early detection

When kidney disease is caught early and patients stay employed, benefits extend far beyond the exam room. Patients who earn a living contribute to federal and state tax revenue. Employers keep experienced workers on the job, strengthening the workforce productivity and reducing turnover. Early disease detection also reduces overall healthcare spending and taxpayer outlays for disability, Medicare and Medicaid. In short, earlier diagnosis is an investment that pays dividends for patients, employers, taxpayers and public programs alike.

The scale of those potential savings is striking. According to the U.S. Renal Data System (USRDS) 2025 Annual Data Report, Medicare fee-for-service spending for adult beneficiaries with CKD was $141.1 billion in 2023, or 36% of all fee-for-service spending. Younger adults (aged 18 to 65) with CKD made up 8.2% of their age group in that population but accounted for 17.8% of its total costs. Employers feel the cost too. The NKF reports that when an employee develops kidney failure, the employer bears the cost for the first 30 months before Medicare becomes primary, averaging $15,444 per month and totaling nearly $500,000.

Putting patients back in control

Arguably, the most important benefit of early detection by PCPs is both hardest to measure and the most meaningful to patients. Earlier diagnosis and intervention put kidney patients and the doctors they choose to care for them, back in control of their lives. Instead of reacting to a crisis, patients and their trusted physicians can plan together: managing blood pressure and blood sugar, adjusting medications, making lifestyle changes and coordinating with specialists before options run out.

A call to action

America has the opportunity to change its strategy for combatting kidney disease. A new, national kidney disease screening recommendation, empowered PCPs and implementation of the Kidney Care National Plan are the best line of defense against kidney failure. Supporting routine screening of at-risk patients, timely follow-up and early treatment will help millions of Americans protect their health, their livelihoods and their futures. Kidney disease may be silent, but our national response to it does not have to be. It should start upstream, in the primary care office, where the greatest good can be done.

• Mr. Hickey and Mr. Conway are president and vice president of American Association of Kidney Patients (AAKP). Both are kidney disease patients with extensive professional histories across Capitol Hill and appointed service in multiple presidential administrations.

Copyright © 2026 The Washington Times, LLC. Click here for reprint permission.

Story Topics

Please read our comment policy before commenting.